Yttrium-90 Radiotherapy

Yttrium-90 radiotherapy delivers beta radiation targeting tumours through radioactive isotope conjugation. Antibody conjugates target specific tumour antigens. Internal dosimetry predicts tumour dose escalation. Myelosuppression represents primary toxicity. Therapeutic benefit justifies radiation exposure.

Regulatory submissions address radiotherapy safety. Dosimetry calculations guide administration. Post-approval surveillance tracks late effects. Clinical outcomes demonstrate therapeutic efficacy. Emerging isotopes improve targeting specificity.